Minneapolis-based Medtronic earned clearance from the Food and Drug Administration for its CardioInsight Noninvasive 3-D Mapping System.
While cardiac mapping typically involves clinicians inserting a catherter into a patient's heart via an artery or vein, the CardioInisght system relies on a 252-electrode sensor vest worn by the patient to retrieve the same electrical data in the heart.
The system provides electroanatomic 3-D maps of the heart and can identify a wide range of irregular heart rhythms in the upper and lower chambers, according to a news release.
To view an animation of the CardioInsight System in use, click here.
More articles on suply chain:
Shifting drug production back to US could raise prices: 5 takeaways
Mayo Clinic physician: A stripped down FDA would be 'chaotic'
Bard Peripheral Vascular recalls Halo One guiding sheath